Clinical trials: Graft Versus Host Disease in GI Tract
Intestinal GVHD, Steroid Refractory GVHD
Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013
The objective of the ORION study is to explore the changes of gut microbiota composition following MaaT013 administration and its impact on the immune system in GVHD patients.
- Trial name
- ORION (NCT05017688)
- Testing
- Blood and stool sample collection
- Where
- 9 sites in France
- Volunteers
- 40 people
- Sponsor
- MaaT Pharma
Acute-graft-versus-host Disease
Safety and Tolerability of FMT Capsules in Healthy Volunteers
This is a two-part, randomized, double-blind, placebo-controlled, single center study to investigate the safety and tolerability of XBI-302 administered orally in healthy volunteers.
- Trial name
- NCT05352269
- Testing
- XBI-302
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shenzhen Xbiome Biotech Co., Ltd.
Acute Graft-Versus-Host Disease, GIGVHD
A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
The objectives of this trial were to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of intravenous (IV) ALXN1007 in participants with acute graft-versus-host disease (GVHD) of the lower…
- Trial name
- GIGVHD (NCT02245412)
- Testing
- ALXN1007 10 mg/kg once weekly, ALXN1007 20 mg/kg once weekly, ALXN1007 20 mg/kg twice weekly
- Where
- 12 sites in United States, France
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.